Overall rank by patents
#27,296
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 5 technology areas, active 2022–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).
The verdict
Sb-kawasumi holds 10 US patents across 5 technology areas, rank #27,296 of 50,000 tracked assignees.
Sb-kawasumi Laboratories, Inc. has been granted 10 US utility patents between 2022 and 2025, placing Sb-kawasumi Laboratories, Inc. at rank #27,296 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 8.4 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a Foreign Corporation, Sb-kawasumi Laboratories, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Sb-kawasumi sits between Sangenic International Ltd. (10 patents, rank #27,292) and Scribe OPCO, Inc. (10 patents, rank #27,300) - the closest US assignees by grant volume. The composite Innovation Score of 41.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2025, with 10 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Sb-kawasumi Laboratories, Inc.'s 8.4 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Sb-kawasumi Laboratories, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
SANGENIC INTERNATIONAL LTD.
10 patents
SANOVO TECHNOLOGY NETHERLANDS B.V.
10 patents
SASOL TECHNOLOGY (PTY.) LIMITED
10 patents
SAUTER FEINMECHANIK GMBH
10 patents
SCA FOREST PRODUCTS AB
10 patents
SCF PHARMA INC.
10 patents
SCHURTER AG
10 patents
SCRIBE OPCO, INC.
10 patents
SB-KAWASUMI LABORATORIES, INC.
10 patents
What this shows Sb-kawasumi holds 10 patents at rank #27,296, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #27,296 in granted patent volume.
Other assignees with the most granted patents in Sb-kawasumi's primary technology class.
Sb-kawasumi's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
41 Top 34% higher than 66% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 5 | 50.0% |
| 2023 | 3 | 30.0% |
| 2025 | 2 | 20.0% |
Top 5 of 5 technology areas
Overall rank by patents
#27,296
Across all tracked assignees
41.2 out of 100
How to use this portfolio
Sb-kawasumi's 10 grants land it in the top 34% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.